Full Press Release Details
Forward Looking Statements
MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING
STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR
HEMOPURIFIER AND OTHER PRODUCT OFFERINGS ARE SUCCESSFULLY DEVELOPED AND
INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER AND OTHER PRODUCT OFFERINGS,
REGULATORY DELAYS, MANUFACTURING DELAYS, AND OTHER RISKS DETAILED IN OUR SEC FILINGS
ACCESSIBLE ONLINE AT WWW.SEC.GOV OR WWW.AETHLONMEDICAL.COM
A revolutionary platform technology
with broad therapeutic applications
against infectious disease and cancer
The first medical device to selectively remove infectious viruses
and immunosuppressive toxins from circulation
Dual Benefit of Action
Simultaneous Antiviral & Immunotherapeutic
Rapid real-time clearance of
infectious viral pathogens
Clearance of virally-shed and
cancer-secreted toxins
Our Circle of Opportunity
Therapeutic Filtration
The Opportunity To Transition Beyond Kidney Dialysis
| Market Opportunity | Application |
| HCV | standard of care adjunct |
| HIV | drug resistant patients |
| Bioterror & Pandemic Threats | broad-spectrum countermeasure |
| CANCER | immunotherapy / diagnostic / biomarker |
Our Hemopurifier has the advantage of being
delivered through an established global infrastructure
of dialysis stations (90,000+ in U.S. alone)
Additional Infrastructure to Deliver
Hemopurifier Therapy Includes:
CRRT machines already located in hospitals
Portable pump configurations
Home Infectious Disease & Cancer Therapy
Genesis of our Hemopurifier
A 2004 patent submission entitled "A Method
for Removal of Viruses from Blood by Lectin
Affinity Hemodialysis" which issued in 2007
Broadened our intellectual property portfolio
Completed 11 pre-clinical programs that have validated broad-spectrum effectiveness in
capturing infectious viral pathogens
Completed 3 separate human safety studies conducted at the Apollo, Fortis, and Sigma New
Life hospitals in India. (68 treatments)
Demonstrated substantial viral load reductions in HIV and HCV infected patients in the
absence of drug therapy
Initiated HCV adjunct clinical study designed to accelerate benefit of SOC drug therapy
Submitted an IDE to the FDA to initiate human studies in the United States
Established GMP manufacturing and have signed LOI to expand capabilities
Completed 5 pre-clinical programs to validate capture of cancer-secreted exosomes
Exosomes Are Secreted By:
All solid-form tumors
Science Publications
Indicate That Exosomes
Disrupt t-cell signaling
Inhibit cytokine production
Tumor Secreted Exosomes
Pre-Clinical Hemopurifier
Additional Studies (2011)
Therapeutic Opportunity
The Hemopurifier fills a previously unmet medical need in
Provides mechanism to preserve immune function
Serves as an adjunct to improve benefit of established and
candidate cancer therapies
Human Immunodeficiency Virus (HIV)
A Solution to Drug Resistance
Infected dialysis patient
12 treatments / 30 days
Performed in absence of drug
Average per treatment viral load
Improved CD4 t-cell ratios
Why Return to the Biodefense
& Pandemic Threat Space?
HHS is committed to increasing countermeasure support
Focal shift from one-drug-one-bug to broad-spectrum therapies
Countermeasures with commercial market applications now ok
FDA approval not required for stockpile consideration
Non-dilutive funding available in amounts not limited by our
U.S. Department of Health and Human Services
BARDA Industry Day Presentation
A Broad-Spectrum Antiviral Platform Technology
The New BARDA & PHEMCE
Strategic Objectives
To identify and support the development of innovative broad-spectrum:
Strategies that address traditional, enhanced, emerging, and advanced
| Virus | Collaborator |
| Ebola | USAMRIID/CDC |
| Dengue | NIV/WHO |
| Lassa | SFBR |
| West Nile | Battelle |
| H5N1 Avian | Battelle |
| 1918-r Spanish Flu | Battelle |
| 2009 H1N1 Swine | Battelle |
| Monkey Pox | Battelle |
In Vitro Confirmations Against
Bioterror and Pandemic Threats
The Hemopurifier represents the most advanced
broad-spectrum countermeasure against bioterror and
emerging pandemic threats
"The Aethlon Hemopurifier is the
only strategy to address the
breadth of pathogens that could be
weaponized as agents of
Director of USSR Bioweapon Program
Author of "BIOHAZARD"
Active CRADA with USAMRIID
Defining program opportunities with BARDA
Awaiting a BAA from DTRA
Preparing response to BAA (released on 2/8/11) from DARPA
entitled "Dialysis Like Therapeutics"
Hepatitis-C Virus (HCV)
180 million infected
Low response rate to peg-interferon/ribavirin standard of care